First Vaccine for Dengue Disease Prevention Receives FDA Approval
May 2nd 2019The drug application was granted the FDA’s Priority Review designation, as well as a Tropical Disease Priority Review Voucher under a program intended to encourage development of new drugs and biologics for the prevention and treatment of certain tropical diseases.
Read More
Walgreen's, UC College of Pharmacy Partner for Specialty Pharmacy Education
May 1st 2019Partnerships like the UC College of Pharmacy and Walgreens offer opportunities for experience with complex disease states, such as cancer, multiple sclerosis, HIV, and Crohn’s disease, that many students will see after they graduate.
Read More
Bipolar Disorder: Opportunity for Pharmacists to Improve Adherence and Health Outcomes
As highly accessible health care professionals, pharmacists have the opportunity to improve medication adherence and health outcomes of patients with bipolar disorder.
Read More
First Treatment for All Genotypes of Hepatitis C in Pediatric Patients Granted FDA Approval
April 30th 2019The safety and efficacy of the glecaprevir and pibrentasvir in pediatric patients was evaluated during clinical trials of 47 patients with genotype 1, 2, 3 or 4 HCV infection without cirrhosis or with mild cirrhosis.
Read More
Study Shows Drug May Be New Treatment Option for Pediatric Patients with T2D
April 29th 2019Novo Nordisk announced the results of the ELLIPSE trial, which examined efficacy and safety and demonstrated superiority of liraglutide (Victoza) injection 1.8 mg vs placebo, in a presentation at the Pediatric Endocrine Society (PES)/Pediatric Academic Societies (PAS) Annual Meeting in Baltimore, MD, on Sunday.
Read More
FDA Approves Drug to Prevent Serious Cardiovascular Events
April 29th 2019High levels of ‘bad’ cholesterol, also known as low-density lipoprotein cholesterol (LDL-C), increase patients' risk for serious CV events such as heart attack or stroke. Adults who experience a heart attack or stroke have an approximately 1 in t3 chance to have another CV event.
Read More
Pediatric Lupus Treatment Receives FDA Approval
April 27th 2019This is the first time that the FDA has approved a treatment for pediatric patients with SLE. Belimumab has been approved for use in adult patients since 2011. GSK’s application for belimumab use in pediatric patients was granted the FDA’s Priority Review designation.
Read More